%0 English Abstract
%T [Expert consensus on safety management of bone-modifying agents (2024 edition)].
%A  
%A  
%J Zhonghua Zhong Liu Za Zhi
%V 46
%N 7
%D 2024 Jul 23
%M 39034800
暂无%R 10.3760/cma.j.cn112152-20240111-00022
%X Bone-modifying agents are a class of drugs that alleviate a series of bone-related events such as pain, pathologic fracture, spinal cord compression, and hypercalcemia caused by bone metastases, and currently include bisphosphonates and RANKL inhibitors. Due to the widespread use of bone-modifying agents, the adverse effects of them are gradually increasing and affecting patients' quality of life. The Breast Cancer Group, Chinese Medical Doctor Association, and the International Medical Society, Chinese Anti-Cancer Association have organized relevant experts to focus on the treatment of bone metastases of advanced malignant tumors based on evidence-based medicine, discuss the management of adverse reactions to bone-modifying agents and form the consensus. Based on the first Expert Consensus on Safety Management of Bone-modifying Agents in China, this consensus added the definition of osteonecrosis of the jaw related to bone-modifying agents, the occurrence of adverse reactions of bone-modifying drugs reported in the literature, and summarized the clinical experience of clinicians in the management of adverse reactions in practice in recent years, and ultimately, the expert group members discussed and proposed reasonable suggestions to guide clinicians in the safety management of bone-modifying agents.<BR>骨改良药物是一类缓解因骨转移引起的疼痛、病理性骨折、脊髓压迫、高钙血症等一系列骨相关事件药物的总称，目前包括双膦酸盐和RANKL抑制剂。由于骨改良药物广泛应用，其药物的不良反应逐渐增多，并影响患者的生活质量。中国医师协会肿瘤医师分会乳腺癌学组和中国抗癌协会国际医疗交流分会组织相关专家，基于循证医学证据，聚焦晚期恶性肿瘤骨转移的治疗，探讨骨改良药物不良反应的管理并形成共识。共识在我国2021年版的《骨改良药物安全性管理专家共识》基础上增加了骨改良药物相关颌骨坏死的定义，补充了更多骨改良药物不良反应的文献报道，总结了近年临床医师在实践中对不良反应处理的诊疗经验，最终经过专家组成员深入探讨提出合理建议，以指导临床医师对骨改良药物的安全性管理。.